Multiple sclerosis (MS) is an autoimmune disease directed against the Central Nervous System (CNS). Recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression. The reduction of bacterial taxa involved in producing health-promoting metabolites, such as short-chain fatty acids (SCFAs), has been reported in MS patients. SCFAs play an important role in the suppression of inflammation. The levels of SCFAs in the blood of MS patients are significantly reduced when compared to those of healthy controls. Since the intake of dietary fiber increases the growth of SCFA-producing bacteria, we investigated the effect of a high-fiber supplement (HFS) on gut bacteria and immunological parameters in MS patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients
Timeframe: Baseline; and 8 weeks and 12 weeks post-NBT-NM108 treatment.
Examine the Effect of NBT-NM108 on Anaerostipes in MS Patients.
Timeframe: Baseline; and 8 weeks and 12 weeks post-NBT-NM108 treatment.
Effect of NBT-NM108 on Fecal Lcn-2 Levels in MS Patients
Timeframe: Baseline, and 8 weeks and 12 weeks post-NBT-NM108 treatment.